The Davare laboratory’s research goals are directed towards overcoming the therapeutic bottleneck in rare but aggressive pediatric and adult cancers. Oncogenomics-driven big data approaches effectively identify lead drug targets for cancer, but bottlenecks arise from a lack or slower pace of functionally testing, vetting and optimizing leads for therapeutic development. Using complementary in vitro and in vivo experimental model systems coupled with patient-derived genomic data, we have successfully identified driving kinase pathways and validated small-molecule inhibitor therapies for targeting distinct genomic subsets of glioblastoma, sarcoma, medulloblastoma and non-small cell lung cancer. We have active cross-institutional collaborations with clinical oncologists to facilitate transfer of our bench discoveries into clinical trials and as needed, validate clinical findings back at the bench. I combine my expertise and experience in the areas of kinase biology, cell surface receptors, and ion channel physiology with my background in molecular pharmacology to lead this translational research program.